A new test for quickly diagnosing Lyme disease
A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease
This study is working on a quick and easy test for Lyme disease that uses special technology to help doctors find the bacteria that causes it, making it faster and more accurate to diagnose, especially in the early stages when treatment is most effective.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Biopeptides, INC. NIH-funded |
| Lab location | 1 site (Ridgefield, UNITED STATES) |
| Project ID | NIH-10653862 on NIH RePORTER |
What this research studies
This research focuses on developing a rapid, point-of-care diagnostic test for Lyme disease using innovative peptide-based technology. The approach aims to improve the detection of Borrelia burgdorferi, the bacteria responsible for Lyme disease, by utilizing unique peptides that are highly specific to the pathogen. This new assay is designed to be portable and cost-effective, allowing for quicker diagnosis and better patient outcomes, especially in the early stages of the disease. By addressing the limitations of current serological tests, this research seeks to enhance the accuracy and speed of Lyme disease diagnosis.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have been exposed to ticks and are showing early symptoms of Lyme disease.
Not a fit: Patients who have already been diagnosed with Lyme disease and are undergoing treatment may not benefit directly from this research.
Why it matters
Potential benefit: If successful, this research could lead to faster and more accurate diagnoses of Lyme disease, improving treatment outcomes for patients.
How similar studies have performed: While there have been challenges in developing effective Lyme disease diagnostics, the innovative use of peptide-based assays shows promise and builds on previous research efforts.
Where this research is happening
Ridgefield, UNITED STATES
- Biopeptides, INC. — Ridgefield, United States (Active)
Researchers
- Principal investigator: Arnaboldi, Paul Michael — Biopeptides, INC.
- Study coordinator: Arnaboldi, Paul Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.